Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.42 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ARF6 | P62330 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838393 | 0.91 | CASR (0.37) | CASRNPY1RCHEK2ARF6 | |
| SCHEMBL6837686 | 0.88 | EGFR (0.41) | NPY1RPIM1CNR2ACP1CHRM1 | |
| SCHEMBL6840065 | 0.88 | MEN1 (0.42) | CASRNPY1RPIM1ACP1EIF4EBP1 | |
| SCHEMBL6837773 | 0.86 | NPY1R (0.38) | NPY1RPIM1CNR2ACP1PIM3 | |
| SCHEMBL6838600 | 0.86 | NPY1R (0.38) | CASRNPY1RPIM1CNR2ACP1 | |
| SCHEMBL7500056 | 0.85 | NPY1R (0.38) | NPY1RPIM1CNR2ACP1PIM3 | |
| SCHEMBL6838050 | 0.83 | HTR6 (0.38) | NPY1RPIM1CNR2ACP1PIM3 | |
| SCHEMBL6837741 | 0.83 | NPY1R (0.37) | NPY1RPIM1CNR2ACP1PIM3 | |
| SCHEMBL6833773 | 0.82 | NPY1R (0.37) | NPY1RPIM1CNR2ACP1EIF4EBP1 | |
| SCHEMBL6837746 | 0.82 | NPY1R (0.41) | NPY1RPIM1CNR2ACP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | CASR 2571/4885NPY1R 1070/4885PIM1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.